Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Current Deferred Revenue: 2022-2024

Historic Current Deferred Revenue for BridgeBio Pharma (BBIO) over the last 3 years, with Dec 2024 value amounting to $14.6 million.

  • BridgeBio Pharma's Current Deferred Revenue fell 22.80% to $9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.1 million, marking a year-over-year decrease of 22.80%. This contributed to the annual value of $14.6 million for FY2024, which is 139.57% up from last year.
  • BridgeBio Pharma's Current Deferred Revenue amounted to $14.6 million in FY2024, which was up 139.57% from $6.1 million recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's Current Deferred Revenue ranged from a high of $14.6 million in FY2024 and a low of $6.1 million during FY2023.
  • Moreover, its 3-year median value for Current Deferred Revenue was $8.2 million (2022), whereas its average is $9.6 million.
  • In the last 5 years, BridgeBio Pharma's Current Deferred Revenue dropped by 25.26% in 2023 and then skyrocketed by 139.57% in 2024.
  • BridgeBio Pharma's Current Deferred Revenue (Yearly) stood at $8.2 million in 2022, then dropped by 25.26% to $6.1 million in 2023, then soared by 139.57% to $14.6 million in 2024.